Outlook Healthy for Life Sciences M&A, IPOs

Paul Hastings Equity Capital Markets co-head and Corporate Life Sciences co-chair Seo Salimi and M&A and Shareholder Activism and Defense partner Andrew Goodman co-authored a Daily Journal article forecasting anticipated life sciences IPO and M&A activity for 2025. The piece addresses developments such as the shift in capital raising opportunities for life sciences companies in the past five years and the Biden administration’s approach to antitrust law and enforcement, ultimately concluding that despite today’s fluid political climate, momentum on the capital markets and M&A fronts is expected in the second half of this year for life sciences companies.